BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 03, 2007
 |  BioCentury  |  Strategy

Buying the Pharm(ion)

Celgene Corp. hopes its acquisition of the 95% of Pharmion Corp. it didn't already own for $2.9 billion in cash and stock will broaden its position in the hematology/oncology space by providing it with rights to a number of marketed products, including Vidaza azacitidine and thalidomide, boost its commercial operations in the U.S. and Europe, and enhance its late-stage pipeline with multiple cancer products in or on the cusp of Phase III testing.

Sol Barer, CELG's chairman and CEO, said on a conference call that the primary driver of the deal was Vidaza, which has been marketed in the U.S. since 2004 to treat myelodysplastic syndromes (MDS). The drug recently received a shot in the arm thanks to...

Read the full 582 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >